Palbociclib-d8

• Description:

  Palbociclib-d8 is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1].

• Product Name Alternative:

  PD 0332991-d8

• UNSPSC:

  12352005

• Hazard Statement:

  H341, H361, H373, H411

• Target:

  CDK; Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Cell Cycle/DNA Damage; Others

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Purity:

  99.84

• Solubility:

  DMSO : 1mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 8.33 mg/mL (ultrasonic; warming; adjust pH to 3 with HCl; heat to 80°C)

• Smiles:

  O=C1N (C2=NC (NC3=NC=C (C=C3) N4C ([2H]) (C ([2H]) (NC ([2H]) (C4 ([2H]) [2H]) [2H]) [2H]) [2H]) =NC=C2C (C) =C1C (C) =O) C5CCCC5

• Molecular Formula:

  C24H21D8N7O2

• Molecular Weight:

  455.58

• Precautions:

  H341, H361, H373, H411

• References & Citations:

  [1]Fry DW, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3 (11) :1427-38.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported

• Isoform:

  CDK4; CDK6

• CAS Number:

  1628752-83-9